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Abstract: Purpose: To evaluate saturation of piperacillin elimination in 
adult critically ill patients.  
Patients and methods: Seventeen adult critically ill patients received 
continuous and intermittent infusion piperacillin/tazobactam. 
Piperacillin plasma concentrations (n=217) were analyzed using population 
pharmacokinetic (PopPK) modeling. Post hoc simulations were performed to 
evaluate the type I error rate associated with our study. Unseen data was 
used to validate the final model. The mean error (ME) and root mean 
squared error (RMSE) were calculated as a measure of bias and imprecision 
respectively. 
Results: A PopPK model with parallel linear and non-linear elimination 
best fitted our data. The median and 95% confidence intervals for model 
parameters drug clearance (CL), volume of the central compartment (V), 
volume of the peripheral compartment (Vp) and intercompartmental 
clearance (Q) were 9 (7.69 - 11) L/h, 6.18 (4.93 - 11.2) L, 11.17 (7.26 - 
12) L and 15.61 (12.66 - 23.8) L/h. The Michaelis-Menten constant (Km) 
and the maximum elimination rate for Michaelis-Menten elimination (Vmax) 
were estimated without population variability in the model to avoid 
overfitting and inflation of the type I error rate. The population 
estimates for Km and Vmax were 37.09 mg/L and 353.57 mg/h respectively. 
The ME was -20.8 (95% CI -26.2; -15.4) mg/L while imprecision (RMSE) was 
49.2 (95% CI 41.2; 56) mg/L 
Conclusion: Piperacillin elimination is (partially) saturable.  Moreover, 
the population estimate for Km lies within the therapeutic window and 
therefore saturation of elimination should be accounted for when defining 







I am writing to resubmit our revised manuscript entitled, “Saturable elimination of 
piperacillin in critically ill patients: implications for continuous infusion”, for consideration 
for publication in the International Journal of Antimicrobial Agents. 
 
We have carefully reviewed the suggestions of reviewer #1. All questions have been 
addressed and changes in the manuscript and figures have been made where necessary.  
A clean version as well as a version with the changes highlighted in yellow are submitted. 
 
This manuscript describes original work and is not under consideration by any other journal. 
All authors approved the revised manuscript and this submission. 
 
Thank you for receiving our revised manuscript and considering it for review. We appreciate 
your time and look forward to your response. 
 
Kind regards, 
Sofie Dhaese, MD 
Dept of Critical Care Medicine 
Ghent University Hospital 
Cover Letter
Reply to the reviewers’ comments 
 
1. As pointed by the author, the study has several short comes: the between-subject 
variability was not estimated for Km and Vmax; urine samples were not collect 
impeding the determination of the renal and non-renal clearance; the final popPK 
model presented a bias towards underpredicting PIP concentrations; a trend in PIP 
clearance over time could not be excluded due to the experimental design (all patients 
received continuous infusion first followed by intermittent infusion). 
 
Answer: we have carefully listed the shortcomings of our paper as we believe this 
information is vital for the interpretation of our results. 
We did not collect urine samples to determine the renal and non-renal component of 
piperacillin clearance but this does not impede the evaluation of whether or not 
piperacillin clearance is nonlinear. The potential bias because of a trend in PIP clearance 
over time is indeed inherent to our study design. However, the time interval between the 
measurements was minimal. Also, to our knowledge, very few PK studies have used a 
design with random assignment to either intermittent or continuous infusion and a switch 
after a certain time to evaluate the behavior of piperacillin clearance. Aside from 
shortcomings, our study also has some specific strengths, not specifically mentioned in 
our manuscript. We have listed our strengths in response to the general comment of 
reviewer #1: 
a) Type-I error calculations. 
We have used a network with a very large computational power to be able to 
determine our type-I error rate. The type-I error rate, in our case 6.6%, tells us 
something about the probability to falsely reject the zero hypothesis (H0, i.e. 
*Detailed Response to Reviewers
piperacillin clearance is linear). Overfitting of data, which happens when one wants to 
estimate too many parameters with too little information, may lead to overly 
optimistic results. In order to obtain a low type-I error rate, we needed to reduce the 
number of estimated parameters and hence we were unable to estimate the BSV on 
Km and Vmax. Our low type-I error rate indicates that we have a low probability to 
falsely conclude that piperacillin clearance is nonlinear. We have reviewed other 
articles that either confirm or refute nonlinear kinetics of piperacillin. [1–6]  None of 
these articles provides this type-I error rate information, nor other information about 
whether or not overfitting was assessed. Hence, we believe that our type-I error 
calculations are a strength of our manuscript in comparison with other articles on this 
specific topic. In this context, we presented an abstract at the PAGE conference in 
Stockholm (June 2019), available via (https://www.page-
meeting.org/default.asp?abstract=8894). The main message of this abstract that is that 
the design of PopPK studies evaluating (non)linear kinetics of piperacillin was far 
from optimal. We believe our efforts to characterize the type-I error rate are a step 
into the right direction. Also, type-I error calculations for PopPK studies are highly 
recommended by the IDeAl consortium. [7]   
b) External validation. 
Another strength of our manuscript is the fact that we have validated our PK model in 
a subset of patients different from the ones used for model building, a vital step in 
model building often lacking in PopPK studies. 
Indeed, our model shows a trend towards underprediction but whether or not a trend 
towards under- or overprediction is also present in the other PopPK studies assessing 
the (non)linear behavior of piperacillin is unknown since none were validated.  
 
2. Besides those, others can be added: artierial blood samples were collected from 
patients instead of venous blood samples (why?/); 
 
Answer: There are several reasons for the use of arterial blood samples. First, patients 
admitted to our ICU have a dedicated arterial bloodline for sampling. It is therefore custom in 
our ICU (and other ICU’s) to use the arterial line for sampling. Second, arterial blood 
samples for antibiotic concentrations have been used by several other authors. [8,9]  
Moreover, unlike high extraction ratio drugs such as e.g. propofol, there is no significant 
arterial-venous difference for piperacillin (personal communication dr Suzanne Parker, 
University Of Queensland, Brisbane, Australia).  
 
3. The values of AUC predicted by Monte Carlo simulations were not that different for 
both dosing regimens (Figure 5). Furthermore, free AUC values should have been 
considered instead of total AUC. Assuming the Clinical and Laboratory Standards 
Institute susceptibility breakpoint for PIP/TZB of ≤16/4 <mu>g/mL, in all dosing 
regimens investigated (Figure 5) plasma concentrations were above the MIC for 
100% of the dosing interval (% T>MIC), not demonstrating the bias towards PIP 
intermittent dosing regiments mentioned by the authors. 
 
Answer: We agree with the reviewer. Whether or not free concentrations were used was, by 
mistake, not stated in our methods section for which apologize. The AUC simulations 
performed in the manuscript were calculated unbound (free) AUC simulations (AUCu) 
assuming a level of protein binding of 30%, which is in accordance with earlier findings. [10]  
We have now added this to our methods section (lines 206-207). We also changed AUC to 
AUCu in our manuscript, including figure 5. The actual numbers did not change as these 
values were already (calculated) unbound AUC values. 
Further, our study was not intended to provide an answer to the question if the difference in 
AUCu between both modes of infusion is of clinical relevance. We believe this question is 
best answered with a study looking at patient outcome. We merely demonstrate that 
administering the same dose using different modes of infusion does not necessarily lead to 
the same antibiotic exposure.  
The reviewer further states that 100%fT>MIC was achieved in all simulations. We agree, yet 
achieving 100% fT>MIC with either intermittent or continuous infusion does not guarantee the 
same level of bacterial cell kill. In another project, we’ve specifically looked at preclinical 
experiments assessing bacterial cell kill with intermittent or prolonged infusion of beta-
lactam antibiotics (protocol available via PROSPERO (CRD42018085202). The majority of 
the experiments with intermittent infusion report a PK/PD target of 40-70% fT>MIC for 
maximum bacterial cell kill, while continuous infusion experiments most commonly report a 
Css/MIC ratio of 4-8 as the preferred PK/PD target for maximal bacterial cell kill. To our 
knowledge, there is no evidence available that indicates that attaining 100%fT>MIC with 
intermittent infusion will lead to the same level of bacterial cell kill as 100%fT>MIC achieved 
with continuous infusion. For example, Alou, et al. [11]  evaluated the PK/PD target for 
intermittent and continuous infusion ceftazidime in an in vitro P. aeruginosa model. For the 
same PK/PD target (i.e. 100%fT>MIC), regrowth was seen in the continuous infusion arm 
while a 3-log10 kill was seen in the intermittent infusion arm. Of note, the AUC in the 
intermittent arm was approximately four times higher when compared with the AUC in the 
continuous infusion arm. Also, Felton, et al. [12]  document different (up to 3-fold higher) 
PK/PD targets for the same level of bacterial cell kill with extended as opposed to 
intermittent infusion piperacillin. Therefore, we think it is not appropriate to compare 
intermittent and continuous infusion in terms of the same PK/PD target (in casu 100%fT>MIC). 
Comparing intermittent and continuous infusion in terms of AUC is a validated strategy and 
was previously done by Firsov and Mattie. [13]  This reference was also added in our 
methods section on line 204-206. 
 
4. Once again, simulations of free plasma concentrations, considering PIP protein 
binding should have been performed. 
 
Answer: Thank you, we have made the necessary changes (see also answer to question 3). 
 
5. Finally, the authors conclude that other studies should be conducted, appropriately 
powered and with low type I error, to provide a conclusive evidence of the potential 
influence on PIP non-linear elimination on critically ill patients treatment, informing 
that the main goal of the study was not achieved. I would add that the Monte Carlo 
simulations should consider the investigation of the proper PK/PD index for this drug 
and no the total AUC proposed in the manuscript. In conclusion, the novelty and the 
advance in knowledge brought by the study are not clear and seem to be of little 
clinical significance. 
 
Answer: Our comment in terms of appropriately powered studies with a low type I error rate 
refers to the fact that, aside from our study, no other study evaluating the (non)linear kinetics 
of piperacillin mentioned some kind of evaluation or external validation of the study design 
(see also strengths of our study as a reply the to the first general remark of reviewer #1). We 
believe we achieved the main goal of our study, given the low likelihood of falsely rejecting 
H0 as demonstrated by the low type-I error rate of our design. It is evident that one can 
always do better, but we are confident that our approach was certainly not inferior to the 
approach of other groups. 
We do not claim at any point AUC/MIC is the PK/PD index of choice for beta-lactam 
antibiotics (as stated on line 341 in our discussion). We merely use AUC/MIC to compare 
two modes of infusion (see also answer to question 3).  
As to the question whether our findings are of clinical relevance, we would argue that there 
are indeed many potential implications. Given the fact that two modes of infusion (i.e. 
intermittent and continuous infusion) cannot be compared based on one single %fT>MIC, a 
comparison in terms of AUC is more appropriate (see also reply to question 3).  
For the purpose of our systematic review and meta-analysis (registered on PROSPERO, see 
also answer to question 3), we have selected original preclinical experiments reporting a 
PK/PD target for beta-lactam antibiotics based on dose finding studies. Second, we calculated 
the AUCu/MIC corresponding to the PK/PD target reported in the original experiment (i.e. a 
PK/PD target of 50%fT>MIC corresponded to an AUCu/MIC of 356 mg*h/mL). Next, we 
calculated the AUCu 24/MIC required to obtain a 1-log10 reduction in CFU/mL in all 
experiments. A DL random-effects model was used to compare mean (+SD) values of AUCu 
24/MIC for intermittent and continuous infusion experiments. We hypothesized that if 
continuous infusion has improved killing characteristics when compared to intermittent 
infusion, then this should be evident from a lower overall antibiotic exposure (AUCu 24/MIC) 
required to achieve the same level of bacterial cell kill. This research question has been 
answered in our review. The first draft has the approval of prof De Waele and prof Lipman 
and currently awaits approval of the other co-authors. 
A difference in AUCu/MIC is especially relevant for large RCT’s comparing intermittent 
versus prolonged infusion of beta-lactam antibiotics. As you may now, the BLING III (Beta-
Lactam Infusion Group) study, a large, 7000-patient RCT aiming to compare intermittent and 
continuous infusion piperacillin and meropenem in terms of all-cause mortality on day 90 is 
currently ongoing. In this study, as in many other RCT’s evaluating intermittent versus 
continuous infusion, the same doses are used in both arms. Our current study clearly 
demonstrates that administering the same dose with intermittent or continuous infusion does 
not necessarily lead to the same exposure. We found a higher exposure in the intermittent 
arm which – when extrapolated to the BLING-III study could impact the results. As we have 
seen with the experiment by Alou, et al. [11] , differences in AUC, although the same 
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x Elimination of piperacillin (PIP) is saturable at therapeutic concentrations 
x Same dose continuous PIP results in lower exposure compared with intermittent PIP 
x Intermittent vs continuous PIP trials may be biased towards intermittent PIP 
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Abstract 37 
Purpose: To evaluate saturation of piperacillin elimination in adult critically ill patients.  38 
Patients and methods: Seventeen adult critically ill patients received continuous and 39 
intermittent infusion piperacillin/tazobactam. Piperacillin plasma concentrations (n=217) 40 
were analyzed using population pharmacokinetic (PopPK) modeling. Post hoc simulations 41 
were performed to evaluate the type I error rate associated with our study. Unseen data was 42 
used to validate the final model. The mean error (ME) and root mean squared error (RMSE) 43 
were calculated as a measure of bias and imprecision respectively. 44 
Results: A PopPK model with parallel linear and non-linear elimination best fitted our data. 45 
The median and 95% confidence intervals for model parameters drug clearance (CL), volume 46 
of the central compartment (V), volume of the peripheral compartment (Vp) and 47 
intercompartmental clearance (Q) were 9 (7.69 – 11) L/h, 6.18 (4.93 – 11.2) L, 11.17 (7.26 – 48 
12) L and 15.61 (12.66 – 23.8) L/h. The Michaelis-Menten constant (Km) and the maximum 49 
elimination rate for Michaelis-Menten elimination (Vmax) were estimated without population 50 
variability in the model to avoid overfitting and inflation of the type I error rate. The 51 
population estimates for Km and Vmax were 37.09 mg/L and 353.57 mg/h respectively. 52 
The ME was -20.8 (95% CI -26.2; -15.4) mg/L while imprecision (RMSE) was 49.2 (95% CI 53 
41.2; 56) mg/L 54 
Conclusion: Piperacillin elimination is (partially) saturable.  Moreover, the population 55 
estimate for Km lies within the therapeutic window and therefore saturation of elimination 56 
should be accounted for when defining optimum dosing regimens for piperacillin in critically 57 
ill patients.  58 
 59 
Keywords: piperacillin, pharmacokinetics, critically ill, saturation  60 
 
Introduction 61 
The ureïdopenicilin piperacillin combined with the beta-lactamase inhibitor 62 
tazobactam is frequently used to treat serious infections in critically ill patients [1,2]. In line 63 
with other beta-lactam antibiotics, piperacillin has time-dependent killing properties. The 64 
time (T) for which the free (f) concentration of piperacillin remains above the minimal 65 
inhibitory concentration (MIC) is the pharmacokinetic/pharmacodynamic (PK/PD) index of 66 
choice, i.e. %fT>MIC [3].  67 
In the past few years, a wealth of evidence emerged demonstrating that the PK of 68 
antimicrobial drugs in critically ill patients is profoundly different from the PK of 69 
antimicrobial drugs in healthy volunteers or non-critically ill patients [4]. For beta-lactam 70 
antibiotics specifically, changes in volume of distribution and/or changes in renal function in 71 
critically ill patients may lead to considerable between- and within-patient PK variability [5]. 72 
Previously, a pharmacokinetic point-prevalence study of beta-lactam antibiotics in the ICU 73 
reported that 16% of the ICU patients did not achieve the PK/PD target of 50%fT>MIC [6]. As 74 
suboptimal antimicrobial use may lead to poor infection outcome, efforts are made to 75 
optimize the use of beta-lactam antibiotics [7–9]. Because beta-lactam antibiotics have time-76 
dependent killing properties, prolonging the duration of beta-lactam infusion and thereby 77 
extending the time the concentration remains above the MIC, was recently introduced in 78 
clinical practice [10,11].  79 
Currently, there is an ongoing debate on whether or not piperacillin elimination is 80 
saturable at therapeutic plasma concentrations [12–19]. This mechanism is particularly 81 
relevant in the context of the recent introduction of prolonged infusion of beta-lactam 82 
antibiotics. Indeed, saturation of piperacillin elimination at therapeutic plasma concentrations 83 
implies that, for the total antibiotic exposure in a patient to be the same, a higher daily dose 84 
could be necessary when piperacillin is infused continuously as opposed to intermittently. In 85 
 
clinical practice however, the total daily dose of piperacillin is usually not adapted based on 86 
the mode of infusion used [11,20]. 87 
The aim of this study was to investigate saturation of piperacillin elimination in 88 
critically ill patients receiving both intermittent and continuous infusion piperacillin.  89 
 90 
Patients and methods 91 
1. Patients 92 
This prospective interventional study was conducted in the Department of Critical 93 
Care Medicine of Ghent University Hospital (Ghent, Belgium). Ethical approval was 94 
obtained from the Ghent University Hospital Ethics Committee (registration number 95 
2017/1354). Informed consent was signed by patients or their representatives. Patients were 96 
eligible for inclusion if they were admitted to the surgical or medical ICU and received 97 
piperacillin/tazobactam (TZP) in continuous infusion. Patients younger than 18 years of age 98 
and patients receiving extracorporeal membrane oxygenation (ECMO) or renal replacement 99 
therapy (RRT) during antibiotic therapy were excluded from the study. Creatinine clearance 100 
was determined by measuring urinary creatinine concentrations from an 8-hour urinary 101 
collection using an indwelling urinary catheter. Piperacillin antibiotic concentrations and 102 
additional data such as, biochemistry, demographic data, the modified Sequential Organ 103 
Failure Assessment score (SOFA) on the day of sampling, the Acute Physiology and Chronic 104 
Health Evaluation (APACHE II) score on admission and ICU survival were prospectively 105 
recorded via REDCap [21]. 106 
 107 
2. Administration of piperacillin antibiotic therapy and sampling 108 
All patients received both continuous and intermittent infusion TZP. TZP dosing was 109 
as follows: loading dose of 4/0.5 g /30 min immediately followed by a continuous TZP 110 
 
infusion: (measured creatinine clearance (CLCR) <15 mL/min: 8/1 g /24 h, CLCR 15-29 111 
mL/min: 12/1.5 g /24h and for a CLCR t 30 mL/min 16/2 g/24h). At the end of the antibiotic 112 
course as indicated by the treating physician, after a 3-hour washout period, a short infusion 113 
(0.5 h; 4500 g) of TZP was administered. In total, 13 samples were collected from every 114 
patient. The first two samples were taken 2 hours prior to and immediately before stopping 115 
the continuous infusion. Samples 3-13 were collected immediately before administration of 116 
the intermittent infusion and after 5, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes as 117 
shown in Figure 1. 118 
 119 
3. Bioanalysis of piperacillin plasma concentrations 120 
Arterial blood collected in 4 mL blood tubes (lithium heparin blood collection tubes, 121 
BD Vacutainer®, BD Diagnostics, Erembodegem, Belgium) was sent to the core laboratory of 122 
the Dept. of Laboratory Medicine at the Ghent University Hospital where they were first 123 
stored in a refrigerator at 4°C until they were collected by the toxicology laboratory 124 
technicians. Storage at 4°C was never longer than 24 hours. After transferring to an 125 
Eppendorf tube, plasma samples were centrifuged at 16162xg for 8 minutes (Microfuge 16, 126 
Beckman Coulter, Brea, California). Immediately afterwards, the plasma samples were stored 127 
at -20˚C until analysis. All samples were analyzed within 1 week. The plasma concentration 128 
of piperacillin was determined by ultra-performance liquid chromatography tandem mass 129 
spectrometry (UPLC – MS/MS). Tazobactam concentrations were not analyzed in this study. 130 
The lower limit of quantification (LLOQ) for piperacillin was 1.09 mg/L, the within-run 131 
assay imprecision at LLOQ level was 3.7 %CV and the between-run assay imprecision at the 132 
LLOQ level was 8.1 %CV [22].  133 
 134 
 
4. Population pharmacokinetic model building 135 
  Piperacillin concentration-time data were analyzed using Pmetrics (version 1.5.2; 136 
Laboratory of Applied Pharmacokinetics, Los Angeles, CA, USA), an R-based software 137 
program for non-parametric and parametric pharmacokinetic-pharmacodynamic 138 
population and individual modelling and simulation. We used the non-parametric adaptive 139 
grid (NPAG) algorithm to build a PopPK model for piperacillin administered via continuous 140 
and intermittent infusion [23]. A digital Fortran compiler was used (Gfortran version 6.1; 141 
Free software foundation, Inc. Boston, MA, USA) and the runs were executed using R 142 
(version 3.5.1; The R Foundation for Statistical Computing. Vienna, Austria) and RStudio 143 
(version 1.1.383; RStudio, Inc. Boston, MA, USA). One- and two compartment models were 144 
fitted to the data using subroutines from the Pmetrics library. Modeling concentration-time 145 
data with both linear, parallel linear/Michaelis-Menten and Michaelis-Menten drug clearance 146 
was attempted. Subsequently, the statistical error model with the best fit was selected and 147 
a covariate model was developed. Covariates a priori considered for inclusion in the model 148 
were: measured creatinine clearance, estimated creatinine clearance (Cockroft-Gault 149 
formula), estimated glomerular filtration rate (Modification of Diet in Renal Disease 150 
(MDRD) formula), body weight, age, SOFA score and albumin, based on prior knowledge 151 
and biological plausibility  [4,24–27]. Body weight was included as a primary covariate on 152 
all model parameters, except for Km and Vmax, according to the allometric power model [28].  153 
(1) P Ti  = TVPT1*(WEIGHT/70)**power                         Eq. 1 154 
Where P Ti is the individual parameter value, TVPT1 is the parameter value for a typical adult 155 
with a body weight of 70kg, and power is an allometric exponent fixed to 0.75 for CL and Q 156 
and fixed to 1 for V and Vp. As an initial step, covariates measured creatinine, estimated 157 
creatinine clearance via Cockroft-Gault formula and estimated glomerular filtration rate using 158 
the MDRD formula were tested on the CL parameter as this is biologically plausible. 159 
 
However, only one of these was retained as correlated variables may lead to collinearity and 160 
inflation of the parameter’s standard error [29]. In a next step, forward selection and 161 
backward elimination using the PMstep function in Pmetrics was used to assess the 162 
relationship between covariates and model parameters. The log likelihood ratio test (LRT) 163 
and the Akaike information criterion (AIC) were considered during model building. More 164 
specifically, a difference of 3.84 in the log likelihood was considered significant at the 5% 165 
level when performing the likelihood ratio test for comparing nested models. Estimated 166 
parameters are reported as mean, percent coefficient of variation (%CV) and median with 167 
interquartile range (IQR). The %CV is reported as a measure of between-subject variability 168 
in the model parameters. 95% Confidence intervals were estimated via a non-parametric 169 
bootstrap (n=1000) and quantify the uncertainty on the parameter estimates. 170 
5. Pharmacokinetic model diagnostics 171 
The PopPK model was assessed by visual evaluation of the goodness of fit of the 172 
observed versus a posteriori predicted plots and the coefficient of determination of the linear 173 
regression of the observed-predicted values (r2 close to 1, intercept close to 0) from each run. 174 
The predictive performance was assessed on mean prediction error (bias) and the mean bias-175 
adjusted square prediction error (imprecision) of the population predictions.  176 
Internal model validation consisted of a visual predictive check (VPC) plot. The VPC 177 
(n=10.000) was performed by overlaying the 95% CI of the simulated profiles for 0.05, 0.5 178 
and 0.95 quantiles with the corresponding quantiles of the observed data. 179 
For external model validation, the final model population parameter distributions 180 
were used to predict concentrations for an independent validation dataset. We refer to 181 
Dhaese, et al [30] for a detailed description of this validation dataset. Prediction errors were 182 
evaluated based on the absolute bias (ME) and imprecision (MSE) as described in equation 2 183 
and 3: 184 
 
(2) Absolute bias[  ] (ME) = E[   –  ]                                                                            Eq.2 185 
(3) Absolute imprecision[  ] (MSE) = E[    –   2]                                                         Eq.3 186 
Where    is the predicted piperacillin concentration and   is the observed concentration. The 187 
root mean square prediction error (RMSE) was calculated by taking the square root of MSE. 188 
 189 
6. Comparative AUCu simulations for intermittent and continuous infusion dosing 190 
regimens  191 
Monte Carlo simulations (n=1000) were performed with the final PopPK model to 192 
compare the unbound (u) area under the curve (AUCu) as a measure of total (unbound) drug 193 
exposure between intermittent and continuous infusion dosing regimens. Using AUC as a 194 
basis to compare intermittent and continuous infusion of beta-lactam antibiotics was 195 
previously reported by Firsov and Mattie [31]. Free piperacillin concentrations were 196 
calculated assuming a 30% level of protein binding in accordance with previous findings  197 
[32]. Four different scenarios were evaluated; i.e. a daily dose of 12/1.5g TZP for a patient 198 
with a measured CLCR of 20mL/min, 16/2g TZP for a patient with a measured CLCR of 199 
70mL/min, 16/2g TZP for a patient with a measured CLCR of 130mL/min and 16/2g TZP for 200 
a patient with a measured CLCR of 200mL/min. The body weight for all patients was fixed at 201 
70kg. For each of these four scenarios, both intermittent and continuous infusion dosing 202 
regimens were simulated and compared. The AUCu was calculated using linear trapezoidal 203 
approximation. A 24-hour interval for AUCu calculation was chosen after six doses for 204 
intermittent infusion and one bolus and five maintenance doses for continuous infusion.  205 
 206 
7. Post hoc estimation of type I error rate  207 
A type I error rate analysis was performed to evaluate the probability to reject the null-208 
hypothesis (H0) in favor of the alternative hypothesis (H1) given that it is true, where H0 = 209 
 
piperacillin kinetics are best described by linear elimination and H1= piperacillin kinetics are 210 
best described by non-linear elimination. [27]  211 
In short, we simulated concentrations for 17 patients according to the design of this study 212 
(drug administration, blood sampling, etc.). For this, the PopPK model by Landersdorfer, et 213 
al [12] served as the H1, i.e. piperacillin PKs are non-linear and elimination is characterized 214 
by a parallel first-order and Michaelis-Menten process. The H0 was simulated by fixing the 215 
Vmax estimate in the model by Landersdorfer to zero, i.e. removing the non-linear component 216 
in piperacillin elimination. This process was repeated 5000 times, resulting in 10,000 217 
simulated datasets. All simulated datasets were fitted with a two-compartmental model with 218 
linear elimination and a two-compartmental model with parallel linear and Michaelis-Menten 219 
elimination. Both models were compared using the LRT according to equation 4.  220 
(4) LRT = 2*(LLc – LLr)                                                             Eq. 4 221 
where LLc is the log likelihood (LL) for the more complex model and LLr is the LL 222 
for the reduced model. The difference in the number of parameters between both models was 223 
4 when between-subject variability was included in the estimation of Km and Vmax and was 2 224 
otherwise. When considering the 5% level of significance, the critical values from the chi-225 
square distribution were 9.49 and 5.99, respectively.  226 
The type I error rate was calculated from the number of times the complex model was 227 
declared superior over the reduced model for the simulated datasets according to the H0.  228 
 229 
8. Statistical analysis 230 
All statistical analyses were performed using R and RStudio. Continuous data are 231 




1. Patients and samples 235 
In total, 17 patients were included, and 221 samples were collected (Table 1). All patients 236 
were enrolled between 5/2/2018 and 18/10/2018. Samples 5-7 were lost for patient 13 and 237 
sample 8 was lost for patient 15, therefore only 217 samples were analyzed and used for PK 238 
model building. The focus of infection was respiratory in 11 patients, abdominal in 5 patients 239 
and bacteremia in 1 patient.  240 
 241 
2. Pharmacokinetic model building and model diagnostics 242 
Table 2 summarizes the log-likelihood values, the coefficients of determination (r2 243 
values), the AIC’s and the predictive performance of linear, parallel linear and Michaelis-244 
Menten and Michaelis-Menten models (without covariates). Comparison of the coefficient of 245 
determination, the bias, imprecision and AIC indicated that the model with parallel linear and 246 
Michaelis-Menten kinetics was superior compared to both a model with linear elimination 247 
and a model with Michaelis-Menten elimination alone (Table 2).  248 
Including measured creatinine clearance (mCRCL) normalized to 100 mL/min as 249 
opposed to estimated creatinine clearance using the Cockroft-Gault or the estimated 250 
glomerular filtration rate using the MDRD formula provided the model with the lowest AIC 251 
value (Table 3). Forward selection and backward elimination further revealed a relationship 252 
between albumin and clearance. However, when including albumin as a covariate on CL, no 253 
model improvement in terms of 'AIC or LRT was noted, hence albumin was not retained as 254 
a covariate in the final model. 255 
The final model was described as: 256 
(5) CL = TVCL*(mCLCR/100) *(WEIGHT/70)**0.75             Eq. 5 257 
(6) V = TVV*(WEIGHT/70)                                                 Eq. 6 258 
(7) Vp = TVVp * (WEIGHT/70)                                                 Eq. 7 259 
 
(8) Q = TVQ* (WEIGHT/70)**0.75                                     Eq. 8 260 
where CL is piperacillin clearance, V is volume of distribution of the central compartment, 261 
Vp is volume of distribution of the peripheral compartment and Q is the intercompartmental 262 
clearance. TVCL refers to the population typical piperacillin clearance for a 70-kg patient 263 
with a mCLCR of 100 mL/min, TVV and TVVp refer to the population typical volume of 264 
distribution of the central, respectively the peripheral compartment for a 70-kg patient.  265 
 The mean, %CV, median (IQR) and %95 CI around the median for the population 266 
parameter estimates are listed in Table 4. The typical value for Km and Vmax was 37.09 mg/L 267 
and 353.57 mg/h respectively.  268 
Between-subject variability was not estimated on Km and Vmax as this resulted in an over-269 
parameterized model and an unacceptable inflation of the type I error rate (for further details 270 
see the section “Post hoc estimation of type I error rate”). Based on the diagnostic plots, the 271 
γ multiplicative error model was selected for modelling assay variance. In all model-building 272 
runs, each observation was weighted by 1/ (γ x SD2). We set γ equal to 1 initially and allowed 273 
Pmetrics to fit the value for the population. The final-cycle γ value was 1.26, indicating some 274 
additional process noise. The formula for the γ error model is error= γ*SD where SD is the 275 
standard deviation of each observation. SD is modeled by equation 9 and was based on 276 
earlier validation work by Carlier, et al [33]. 277 
(9) SD = 2 + 0.1x C                                                                                                       Eq. 9 278 
where C is the concentration of piperacillin. 279 
The a posteriori individual and population predicted versus observed plots and the 280 
VPC plots are shown in figure 2 and 3 respectively. The results of the Shapiro-Wilk test of 281 
normality for the NPDE indicated no violation of normality (p=.195). 282 
 
The final PopPK models showed a bias (ME) in predicting serum concentrations from the 283 
validation dataset of -20.8 (95% CI -26.2 ; -15.4) mg/L while imprecision (RMSE) was 49.2 284 
(95% CI 41.2 ; 56) mg/L. The Bland-Altman plot is shown in figure 4. 285 
 286 
3. Comparative AUCu simulations for intermittent and continuous infusion dosing 287 
regimens  288 
In all four scenarios, patients receiving continuous infusion had lower AUCu values when 289 
compared to simulated patients receiving the same dose via intermittent infusion (figure 5).  290 
 291 
4. Post hoc estimation of type I error rate  292 
If the between-subject variability was estimated for all model parameters, the type I error 293 
rate was 47.9%. If the between-subject variability was estimated for CL, Q, V and Vp and not 294 
estimated for Km and Vmax, the type I error rate was reduced to 6.6%. 295 
 296 
Discussion 297 
A PopPK model with parallel linear and Michaelis-Menten elimination of piperacillin 298 
best described this data, collected from 17 critically ill patients receiving both intermittent 299 
and continuous infusion piperacillin/tazobactam. These findings are in agreement with 300 
previous studies in healthy volunteers and non-critically ill patients [12,13,17] and in 301 
disagreement with other studies in healthy volunteers and critically ill patients [14,30,34].  302 
Renal excretion of piperacillin is the major pathway of elimination. Approximately 303 
74-89% of the administered dose of piperacillin is eliminated from the body by renal 304 
excretion [2,35]. More specifically, Tjandramaga, et al. [35] reported that 56-73% of the 305 
renally cleared piperacillin is eliminated through tubular secretion, which is a saturable 306 
process.  307 
 
Vmax is the maximum elimination rate for Michaelis-Menten elimination and the drug 308 
concentration at which the elimination rate is half of the maximum elimination rate is called 309 
the Michaelis-Menten constant or Km. Whether or not non-linear elimination of a drug is 310 
clinically relevant depends on the value of Vmax and Km. Non-linear elimination is a clinically 311 
relevant process if saturation occurs at therapeutic concentrations (i.e. Km within the 312 
therapeutic window) and if Vmax is high relative to CL, indicating a substantial contribution 313 
of the non-linear elimination process to the total body clearance. It is postulated that the non-314 
linear elimination pathway should contribute to at least 20% of the total body clearance for it 315 
to be clinically relevant [36]. If Km is very high, then saturation occurs but not at relevant 316 
plasma concentrations and it will therefore have no impact on the optimal dosing regimen 317 
[12]. Other researchers have reported Km estimates of 36.1 mg/L [12], 47.9 mg/L [13] and 318 
90.13 mg/L [17], all well in the range of therapeutic piperacillin plasma concentrations and in 319 
line with our estimate of 37.09 mg/L.  320 
The implications of these findings remain to be determined. Several institutions 321 
recently moved towards prolonged infusion of beta-lactam antibiotics yet conclusive 322 
evidence in favor of prolonged infusion is lacking and new clinical trials are in the pipeline 323 
[10,11,20,37]. Saturation of piperacillin elimination at therapeutic plasma concentrations is of 324 
particular relevance when randomized clinical trials compare intermittent versus continuous 325 
infusion piperacillin. Indeed, if saturation of piperacillin elimination occurs at therapeutic 326 
concentrations, clinical trials comparing the same daily dose of intermittent and continuous 327 
infusion piperacillin may unwillingly introduce a bias towards intermittent infusion as 328 
patients receiving the same daily dose of piperacillin via intermittent infusion may have a 329 
higher total antibiotic exposure when compared to patients receiving the same dose of 330 
piperacillin via continuous infusion as is demonstrated in the AUCu 24 calculations using the 331 
final PopPK model (figure 5). While AUCu/MIC may not be the PD index of choice for beta-332 
 
lactam antibiotics, the phenomenon of non-linear kinetics may impact antibiotic 333 
concentrations and indirectly also other PD indices such as T>MIC. This study focused on 334 
piperacillin but tubular secretion of other beta-lactam antibiotics such as amoxicillin, 335 
oxacillin, flucoxacillin, cefazolin and cefuroxime has been reported as well [38,39].   336 
When performing hypothesis testing and PK model selection, control of the type I 337 
error rate is pivotal to avoid false positive conclusions. Inflation of the type I error rate is 338 
expected when dealing with (very) small datasets [40,41]. In this study, including the 339 
between-subject variability on Km and Vmax resulted in an over-parameterized model and an 340 
unacceptable type I error rate (for further details see the section “Post hoc estimation of the 341 
type I error rate”). Therefore, the between-subject variability for Km and Vmax was not 342 
estimated. As few piperacillin population PK studies incorporate type I error calculations, it 343 
is difficult to determine how our findings with regard to the non-linear kinetics of piperacillin 344 
relate to the findings of other studies.  345 
This study has several limitations. While our primary goal was to detect non-linear 346 
elimination of piperacillin with a low probability of falsely rejecting H0, the between-subject 347 
variability was not estimated on Km and Vmax as this led to an unacceptable type I error. 348 
Determining urinary concentrations of renally eliminated drugs is helpful when non-linear 349 
kinetics are expected, however, in this study, piperacillin concentrations were not measured 350 
in the urine and no distinction could be made between the renal and non-renal clearance of 351 
piperacillin. The validation results indicate that the final model has a bias towards 352 
underpredicting antibiotic concentrations. While no bias is to be preferred, in case of 353 
underprediction, physicians may be inclined to increase the dose or dosing frequency. Given 354 
the low toxicity of beta-lactam antibiotics and the important risk of underdosing in ICU 355 
patients, models that underpredict concentrations of beta-lactam antibiotics are usually 356 
preferred over models that have bias towards overprediction [42]. Additionally, the sequence 357 
 
of the infusion modes never changed and all patients received continuous infusion first, 358 
followed by intermittent infusion. Hence, a trend in piperacillin clearance over time could not 359 
be excluded. 360 
In conclusion, piperacillin elimination was best described by a PopPK model 361 
incorporating parallel linear and Michaelis-Menten elimination. Nevertheless, in literature 362 
conflicting evidence is found on the importance of non-linear elimination for piperacillin PK. 363 
Non-informative study designs, and statistical inference based on over-parameterized models 364 
likely contribute to these conflicting findings. Future studies, appropriately powered and with 365 
a low type I error rate, should be conducted to provide conclusive evidence on the potential 366 
influence of non-linear elimination for piperacillin PK in critically ill patients.  367 
 368 
Acknowledgements 369 
The computational resources and services used in this work were provided by the VSC 370 
(Flemish Supercomputer Center), funded by the Research Foundation - Flanders (FWO) and 371 
the Flemish Government – department Economy, Science and Innovation (EWI). 372 
The authors wish to thank the laboratory technicians for analyzing the samples. 373 
 374 
Declarations 375 
Funding: Sofie A.M. Dhaese is funded by a Centre of Research Excellence Grant 376 
(APP1099452) from the Australian National Health and Medical Research Council awarded 377 
to Jason A. Roberts. 378 
Jason A. Roberts would like to recognize funding from the Australian National Health and 379 
Medical Research Council for a Centre of Research Excellence (APP1099452) and a 380 
Practitioner Fellowship (APP1117065).  381 
 
Jan J. De Waele is senior clinical investigator funded by the Research Foundation Flanders 382 
(FWO, Ref. 1881015N). 383 
Competing Interests: Jeffrey Lipman has been a consultant for MSD, Australia and Pfizer. 384 
Jason Roberts has been a consultant for Accelerate Diagnostics, Astellas, 385 
Bayer, bioMerieux and MSD as well as having received investigator-initiated grants from 386 
MSD, The Medicines Company and Cardeas Pharma. 387 
Jan De Waele has been consultant for Accelerate Diagnostics, Bayer Healthcare, MSD and 388 
Pfizer 389 




 [1]  Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, 394 
et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-395 
acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of 396 
hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European 397 
Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), 398 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and 399 
Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017;50. 400 
[2]  Bryson HM, Brogden RN. Piperacillin/tazobactam. A review of its antibacterial 401 
activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506–35. 402 
[3]  Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial 403 
dosing of mice and men. Clin Infect Dis 1998;26:1–10; quiz 11–2. 404 
[4]  Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T, et al. 405 
Individualised antibiotic dosing for patients who are critically ill: challenges and potential 406 
 
solutions. The Lancet Infectious Diseases 2014;14:498–509. 407 
[5]  Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic 408 
review of the pharmacokinetics of β-lactams. Crit Care 2011;15:R206. 409 
[6]  Roberts JA, Paul SK, Akova M, Bassetti M, Waele JJ De, Dimopoulos G, et al. 410 
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic 411 
doses sufficient for critically ill patients? Clin Infect Dis 2014;58:1072–83. 412 
[7]  Roberts JA, Kumar A, Lipman J. Right Dose, Right Now: Customized Drug Dosing 413 
in the Critically Ill. Crit Care Med 2017;45:331–336. 414 
[8]  Roberts JA, Roger C, Waele JJ De. Personalized antibiotic dosing for the critically 415 
ill. Intensive Care Med 2019; 45;5:715-718 416 
[9]  Timsit J-F, Bassetti M, Cremer O, Daikos G, Waele J de, Kallil A, et al. 417 
Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Medicine 418 
2019;45:172–189. 419 
[10]  Charmillon A, Novy E, Agrinier N, Leone M, Kimmoun A, Levy B, et al. The 420 
ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam 421 
administration and therapeutic drug monitoring among critically ill patients in France. Clin 422 
Microbiol Infect 2016;22:625–31. 423 
[11]  Buyle FM, Decruyenaere J, Waele J De, Tulkens PM, Audenrode T Van, Depuydt P, 424 
et al. A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care 425 
units and general wards in Belgian hospitals. Eur J Clin Microbiol Infect Dis 2013;32:763–8. 426 
[12]  Landersdorfer CB, Bulitta JB, Kirkpatrick CM, Kinzig M, Holzgrabe U, Drusano 427 
GL, et al. Population pharmacokinetics of piperacillin at two dose levels: influence of 428 
nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother 429 
2012;56:5715–23. 430 
[13]  Bulitta JBB, Kinzig M, Jakob V, Holzgrabe U, Sörgel F, Holford NH. Nonlinear 431 
 
pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage 432 
regimens. Br J Clin Pharmacol 2010;70:682–93. 433 
[14]  Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and 434 
steady-state population pharmacokinetics and pharmacodynamics of piperacillin by 435 
continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 436 
2010;35:156–63. 437 
[15]  Jeon S, Han S, Lee J, Hong T, Paek J, Woo H, et al. Population Pharmacokinetic 438 
Analysis of Piperacillin in Burn Patients. Antimicrobial Agents and Chemotherapy 439 
2014;58:3744–3751. 440 
[16]  Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB. Population 441 
pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by 442 
prolonged infusion in obese and nonobese patients. J Clin Pharmacol 2015;55:899–908. 443 
[17]  Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, et al. 444 
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized 445 
patients with nosocomial infections. Antimicrob Agents Chemother 2012;56:4087–94. 446 
[18]  Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics 447 
and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with 448 
cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother 2014;69:176–449 
9. 450 
[19]  Vinks AA, Hollander JG Den, Overbeek SE, Jelliffe RW, Mouton JW. Population 451 
pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or 452 
continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 453 
2003;47:541–7. 454 
[20]  Tabah A, Waele J De, Lipman J, Zahar JR, Cotta MO, Barton G, et al. The ADMIN-455 
ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob 456 
 
Chemother 2015;70:2671–7. 457 
[21]  Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic 458 
data capture (REDCap)--a metadata-driven methodology and workflow process for providing 459 
translational research informatics support. J Biomed Inform 2009;42:377–81. 460 
[22]  Carlier M, Stove V, Waele J, Verstraete A. Ultrafast quantification of β-lactam 461 
antibiotics in human plasma using UPLC-MS/MS. Journal of Chromatography B, Analytical 462 
Technologies in the Biomedical and Life Sciences 2015;978-979:89–94. 463 
[23]  Neely M, Guilder M van, Yamada W, Schumitzky A, Jelliffe R. Accurate Detection 464 
of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric 465 
Pharmacometric Modeling and Simulation Package for R. Therapeutic Drug Monitoring 466 
2012;34:467. 467 
[24]  Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, et al. Are standard doses 468 
of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit 469 
Care 2015;19:28. 470 
[25]  Tsai D, Stewart P, Goud R, Gourley S, Hewagama S, Krishnaswamy S, et al. 471 
Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe 472 
Sepsis. Antimicrob Agents Chemother 2016;60:7402–7406. 473 
[26]  Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, et al. Population 474 
Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill 475 
Patients. Antimicrob Agents Chemother 2017;61. 476 
[27]  Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd ed. 477 
New York: Springer; 2011. 478 
[28]  Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in 479 
pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48:303–32. 480 
[29]  Bonate P. Effect of correlation on covariate selection in linear and nonlinear mixed 481 
 
effect models. Pharmaceutical Statistics 2017;16:45–54. 482 
[30]  Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, Waele JJ De. 483 
Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. 484 
Int J Antimicrob Agents 2018;51:594–600. 485 
[31]  Firsov AA, Mattie H. Relationships between antimicrobial effect and area under the 486 
concentration-time curve as a basis for comparison of modes of antibiotic administration: 487 
meropenem bolus injections versus continuous infusions. Antimicrob Agents Chemother 488 
1997;41:352–6. 489 
[32]  Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin 490 
penetration into tissue of critically ill patients with sepsis--bolus versus continuous 491 
administration? Crit Care Med 2009;37:926–33. 492 
[33]  Carlier M, Stove V, Roberts JA, Velde E Van de, Waele JJ De, Verstraete AG. 493 
Quantification of seven β-lactam antibiotics and two β-lactamase inhibitors in human plasma 494 
using a validated UPLC-MS/MS method. Int J Antimicrob Agents 2012;40:416–22. 495 
[34]  Auclair B, Ducharme MP. Piperacillin and tazobactam exhibit linear 496 
pharmacokinetics after multiple standard clinical doses. Antimicrob Agents Chemother 497 
1999;43:1465–8. 498 
[35]  Tjandramaga TB, Mullie A, Verbesselt R, Schepper PJ De, Verbist L. Piperacillin: 499 
human pharmacokinetics after intravenous and intramuscular administration. Antimicrob 500 
Agents Chemother 1978;14:829–37. 501 
[36]  Ginneken CA van, Russel FG. Saturable pharmacokinetics in the renal excretion of 502 
drugs. Clin Pharmacokinet 1989;16:38–54. 503 
[37]  Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. A 504 
Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe 505 
Sepsis. Am J Respir Crit Care Med 2015;192:1298–305. 506 
 
[38]  Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JBB, Holzgrabe U, Sörgel F. 507 
Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol 508 
2008;66:648–59. 509 
[39]  Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar J-WC. 510 
Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on 511 
Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams. 512 
Pharmaceutics 2011;3:865–913. 513 
[40]  Hilgers R-DD, Bogdan M, Burman C-FF, Dette H, Karlsson M, König F, et al. 514 
Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and 515 
analysis of small population clinical trials. Orphanet J Rare Dis 2018;13:77. 516 
[41]  Babyak M. What You See May Not Be What You Get: A Brief, Nontechnical 517 
Introduction to Overfitting in Regression-Type Models. Psychosom Med 2004;66:411–421. 518 
[42]  Dhaese SAM, Farkas A, Colin P, Lipman J, Stove V, Verstraete AG, et al. 519 
Population pharmacokinetics and evaluation of the predictive performance of 520 
pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a 521 
comparison of eight pharmacokinetic models. J Antimicrob Chemother 2019;74:432–441. 522 
 523 
 524 
  525 
 
Captions and legends of tables and figures 526 
Tables 527 
Table 1: Patient characteristics, laboratory data and infection characteristics 528 
 529 
Table 2: Predictive performance of linear and non-linear piperacillin population PK models 530 
Predictive performance of linear, parallel linear and Michaelis-Menten and Michaelis-Menten 531 
model. R2 is the coefficient of determination for the best-fit linear regression for the 532 
predicted-observed plot. LL is the log likelihood estimate. AIC is the Akaike information 533 
criterion. L = linear, MM= Michaelis-Menten. 534 
 535 
Table 3: Predictive performance of piperacillin population PK models incorporating renal 536 
clearance as a covariate 537 
Predictive performance of linear, parallel linear and Michaelis-Menten and Michaelis-Menten 538 
model. R2 is the coefficient of determination for the best-fit linear regression for the 539 
predicted-observed plot. LL is the log likelihood estimate. AIC is the Akaike information 540 
criterion. mCLCR = measured creatinine clearance, GaG = estimated creatinine clearance 541 
using the Cockroft-Gault formula, MDRD = estimated glomerular filtration rate using the 542 
MDRD formula. 543 
 544 
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Figures 551 
Figure 1: Administration of piperacillin and timing of sampling 552 
 553 
Figure 2: The population predicted versus observed concentrations (left) and the individual 554 
predicted versus observed concentrations (right) diagnostic plots for the final PK model. The 555 
dashed line is the line of unity and the solid line is the line of the best linear fit. 556 
 557 
Figure 3: Visual predictive check plot of piperacillin plasma concentrations (log10 scale) vs. 558 
time for the final PopPK model. Black dots represent observed data, solid lines represent 559 
quantiles of the observed data and dashed lines represent quantiles of the simulated data. 560 
 561 
Figure 4: Bland-Altman plot for comparison of predicted versus observed piperacillin 562 
concentrations from a validation dataset. The blue line represents the mean difference in 563 
concentrations. Red lines are mean-1.96*SD (lower line) and mean+1.96*SD (upper line).  564 
 565 
Figure 5: Simulations of mean (sd) AUCu values and time-concentration curves for a total 566 
daily dose of 12/1g PIP (upper graph) or 16g PIP via intermittent (left) or continuous (right) 567 
infusion for a patient with a body weight of 70kg and a measured CLCR of respectively 20, 568 
70, 130 and 200mL/min. AUCu values were calculated for a 24-hour interval after the sixth 569 
dose. 570 
Table 1: Patient characteristics, laboratory data and infection characteristics 
Patient characteristics Median (IQR) or 
count (%) 
Male, n (%) 11 (64.7%) 
Age in years, median (IQR) 64 (51-70) 
Weight in kg, median (IQR) 75 (69-80) 
APACHE II, median (IQR) 20 (14-24) 
SOFA, median (IQR) 7 (5-8) 
Duration of TZP therapy in days, median (IQR) 5.8 (4.3-6.8) 
Mechanical ventilation during TZP therapy, n (%) 13 (76.5%) 
Vasopressive therapy during TZP therapy, n (%) 6 (35.3%) 
ICU length of stay in days, median (IQR) 17.9 (14.1-31.5) 
ICU survival, n (%) 15 (88.2%) 
Albumin in g/L Median (IQR) 
72h prior to sampling 26.5 (22-29.5) 
48h prior to sampling 26 (21-27.5) 
24h prior to sampling 26.5 (22.8-30.3) 
Day of sampling 27 (21.5-30.5) 
24h post sampling 27 (21.5-30.8) 
Timing Estimated creatinine 
clearance (Cockroft-
Gault) in mL/min 
Median (IQR) 
Estimated creatinine 







72h prior to 
sampling 
82.9 (52.3-147.3) 97.9 (49.8-145.6) 70 (30-138) 
48h prior to 
sampling 
85.2 (41.1-139.2) 92.9 (36.5-140.9) 49.5 (16.8-141.5) 
24h prior to 
sampling 
84.7 (39.9-119.3) 70.3 (59.8-78.6) 87 (43-120) 
Day of 
sampling 
86.1 (40.8-139.2) 101.1 (35.2-140.9) 82 (32.5-98) 




Table 2: Predictive performance of linear and non-linear piperacillin population PK models 
 Linear regression of observed-predicted for each 
patient 
 
Model -2LL Intercept Slope r2 Bias Imprecision AIC 
L 1842 3.73 0.98 0.977 -0.078 0.995 1852 
L/MM 1748 5.33 0.96 0.975 -0.147 1.31 1797 
MM 2197 38.9 0.933 0.647 -0.457 0.779 2207 
Predictive performance of linear, parallel linear and Michaelis-Menten and Michaelis-Menten 
model. R2 is the coefficient of determination for the best-fit linear regression for the 
predicted-observed plot. LL is the log likelihood estimate. AIC is the Akaike information 
criterion. L = linear, MM= Michaelis-Menten. 
 
Table 2
Table 3: Predictive performance of piperacillin population PK models incorporating renal 
clearance as a covariate 
 Linear regression of observed-predicted for each 
patient 
 
Model -2LL Intercept Slope r2 Bias Imprecision AIC 
mCLCR 1796 4.87 0.97 0.986 -0.136 1.25 1806 
GaG 1805 6.08 0.959 0.97 -0.172 1.29 1815 
MDRD 1904 5.5 0.98 0.962 -0.12 0.96 1915 
Predictive performance of linear, parallel linear and Michaelis-Menten and Michaelis-Menten 
model. R2 is the coefficient of determination for the best-fit linear regression for the 
predicted-observed plot. LL is the log likelihood estimate. AIC is the Akaike information 
criterion. mCLCR = measured creatinine clearance, GaG = estimated creatinine clearance 




Table 4: Mean, %CV, median (IQR), and 95%CI parameter estimates for the final PopPK 
model 
Parameter Mean  %CV Median (IQR) 95% CI around 
the median 
V (L) 9.74  87.27% 6.18 (5.76 – 6.52) 4.93 – 11.2 
CL (L/h) 9.29  26.19% 9 (8.68 – 9.43) 7.69 – 11 
Q (L/h) 21.47  59.81% 15.61 (13.38 – 20.29) 12.66 – 23.8 
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Abstract 37 
Purpose: To evaluate saturation of piperacillin elimination in adult critically ill patients.  38 
Patients and methods: Seventeen adult critically ill patients received continuous and 39 
intermittent infusion piperacillin/tazobactam. Piperacillin plasma concentrations (n=217) 40 
were analyzed using population pharmacokinetic (PopPK) modeling. Post hoc simulations 41 
were performed to evaluate the type I error rate associated with our study. Unseen data was 42 
used to validate the final model. The mean error (ME) and root mean squared error (RMSE) 43 
were calculated as a measure of bias and imprecision respectively. 44 
Results: A PopPK model with parallel linear and non-linear elimination best fitted our data. 45 
The median and 95% confidence intervals for model parameters drug clearance (CL), volume 46 
of the central compartment (V), volume of the peripheral compartment (Vp) and 47 
intercompartmental clearance (Q) were 9 (7.69 – 11) L/h, 6.18 (4.93 – 11.2) L, 11.17 (7.26 – 48 
12) L and 15.61 (12.66 – 23.8) L/h. The Michaelis-Menten constant (Km) and the maximum 49 
elimination rate for Michaelis-Menten elimination (Vmax) were estimated without population 50 
variability in the model to avoid overfitting and inflation of the type I error rate. The 51 
population estimates for Km and Vmax were 37.09 mg/L and 353.57 mg/h respectively. 52 
The ME was -20.8 (95% CI -26.2; -15.4) mg/L while imprecision (RMSE) was 49.2 (95% CI 53 
41.2; 56) mg/L 54 
Conclusion: Piperacillin elimination is (partially) saturable.  Moreover, the population 55 
estimate for Km lies within the therapeutic window and therefore saturation of elimination 56 
should be accounted for when defining optimum dosing regimens for piperacillin in critically 57 
ill patients.  58 
 59 
Keywords: piperacillin, pharmacokinetics, critically ill, saturation  60 
 
Introduction 61 
The ureïdopenicilin piperacillin combined with the beta-lactamase inhibitor 62 
tazobactam is frequently used to treat serious infections in critically ill patients [1,2]. In line 63 
with other beta-lactam antibiotics, piperacillin has time-dependent killing properties. The 64 
time (T) for which the free (f) concentration of piperacillin remains above the minimal 65 
inhibitory concentration (MIC) is the pharmacokinetic/pharmacodynamic (PK/PD) index of 66 
choice, i.e. %fT>MIC [3].  67 
In the past few years, a wealth of evidence emerged demonstrating that the PK of 68 
antimicrobial drugs in critically ill patients is profoundly different from the PK of 69 
antimicrobial drugs in healthy volunteers or non-critically ill patients [4]. For beta-lactam 70 
antibiotics specifically, changes in volume of distribution and/or changes in renal function in 71 
critically ill patients may lead to considerable between- and within-patient PK variability [5]. 72 
Previously, a pharmacokinetic point-prevalence study of beta-lactam antibiotics in the ICU 73 
reported that 16% of the ICU patients did not achieve the PK/PD target of 50%fT>MIC [6]. As 74 
suboptimal antimicrobial use may lead to poor infection outcome, efforts are made to 75 
optimize the use of beta-lactam antibiotics [7–9]. Because beta-lactam antibiotics have time-76 
dependent killing properties, prolonging the duration of beta-lactam infusion and thereby 77 
extending the time the concentration remains above the MIC, was recently introduced in 78 
clinical practice [10,11].  79 
Currently, there is an ongoing debate on whether or not piperacillin elimination is 80 
saturable at therapeutic plasma concentrations [12–19]. This mechanism is particularly 81 
relevant in the context of the recent introduction of prolonged infusion of beta-lactam 82 
antibiotics. Indeed, saturation of piperacillin elimination at therapeutic plasma concentrations 83 
implies that, for the total antibiotic exposure in a patient to be the same, a higher daily dose 84 
could be necessary when piperacillin is infused continuously as opposed to intermittently. In 85 
 
clinical practice however, the total daily dose of piperacillin is usually not adapted based on 86 
the mode of infusion used [11,20]. 87 
The aim of this study was to investigate saturation of piperacillin elimination in 88 
critically ill patients receiving both intermittent and continuous infusion piperacillin.  89 
 90 
Patients and methods 91 
1. Patients 92 
This prospective interventional study was conducted in the Department of Critical 93 
Care Medicine of Ghent University Hospital (Ghent, Belgium). Ethical approval was 94 
obtained from the Ghent University Hospital Ethics Committee (registration number 95 
2017/1354). Informed consent was signed by patients or their representatives. Patients were 96 
eligible for inclusion if they were admitted to the surgical or medical ICU and received 97 
piperacillin/tazobactam (TZP) in continuous infusion. Patients younger than 18 years of age 98 
and patients receiving extracorporeal membrane oxygenation (ECMO) or renal replacement 99 
therapy (RRT) during antibiotic therapy were excluded from the study. Creatinine clearance 100 
was determined by measuring urinary creatinine concentrations from an 8-hour urinary 101 
collection using an indwelling urinary catheter. Piperacillin antibiotic concentrations and 102 
additional data such as, biochemistry, demographic data, the modified Sequential Organ 103 
Failure Assessment score (SOFA) on the day of sampling, the Acute Physiology and Chronic 104 
Health Evaluation (APACHE II) score on admission and ICU survival were prospectively 105 
recorded via REDCap [21]. 106 
 107 
2. Administration of piperacillin antibiotic therapy and sampling 108 
All patients received both continuous and intermittent infusion TZP. TZP dosing was 109 
as follows: loading dose of 4/0.5 g /30 min immediately followed by a continuous TZP 110 
 
infusion: (measured creatinine clearance (CLCR) <15 mL/min: 8/1 g /24 h, CLCR 15-29 111 
mL/min: 12/1.5 g /24h and for a CLCR t 30 mL/min 16/2 g/24h). At the end of the antibiotic 112 
course as indicated by the treating physician, after a 3-hour washout period, a short infusion 113 
(0.5 h; 4500 g) of TZP was administered. In total, 13 samples were collected from every 114 
patient. The first two samples were taken 2 hours prior to and immediately before stopping 115 
the continuous infusion. Samples 3-13 were collected immediately before administration of 116 
the intermittent infusion and after 5, 30, 45, 60, 90, 120, 180, 240, 300 and 360 minutes as 117 
shown in Figure 1. 118 
 119 
3. Bioanalysis of piperacillin plasma concentrations 120 
Arterial blood collected in 4 mL blood tubes (lithium heparin blood collection tubes, 121 
BD Vacutainer®, BD Diagnostics, Erembodegem, Belgium) was sent to the core laboratory of 122 
the Dept. of Laboratory Medicine at the Ghent University Hospital where they were first 123 
stored in a refrigerator at 4°C until they were collected by the toxicology laboratory 124 
technicians. Storage at 4°C was never longer than 24 hours. After transferring to an 125 
Eppendorf tube, plasma samples were centrifuged at 16162xg for 8 minutes (Microfuge 16, 126 
Beckman Coulter, Brea, California). Immediately afterwards, the plasma samples were stored 127 
at -20˚C until analysis. All samples were analyzed within 1 week. The plasma concentration 128 
of piperacillin was determined by ultra-performance liquid chromatography tandem mass 129 
spectrometry (UPLC – MS/MS). Tazobactam concentrations were not analyzed in this study. 130 
The lower limit of quantification (LLOQ) for piperacillin was 1.09 mg/L, the within-run 131 
assay imprecision at LLOQ level was 3.7 %CV and the between-run assay imprecision at the 132 
LLOQ level was 8.1 %CV [22].  133 
 134 
 
4. Population pharmacokinetic model building 135 
  Piperacillin concentration-time data were analyzed using Pmetrics (version 1.5.2; 136 
Laboratory of Applied Pharmacokinetics, Los Angeles, CA, USA), an R-based software 137 
program for non-parametric and parametric pharmacokinetic-pharmacodynamic 138 
population and individual modelling and simulation. We used the non-parametric adaptive 139 
grid (NPAG) algorithm to build a PopPK model for piperacillin administered via continuous 140 
and intermittent infusion [23]. A digital Fortran compiler was used (Gfortran version 6.1; 141 
Free software foundation, Inc. Boston, MA, USA) and the runs were executed using R 142 
(version 3.5.1; The R Foundation for Statistical Computing. Vienna, Austria) and RStudio 143 
(version 1.1.383; RStudio, Inc. Boston, MA, USA). One- and two compartment models were 144 
fitted to the data using subroutines from the Pmetrics library. Modeling concentration-time 145 
data with both linear, parallel linear/Michaelis-Menten and Michaelis-Menten drug clearance 146 
was attempted. Subsequently, the statistical error model with the best fit was selected and 147 
a covariate model was developed. Covariates a priori considered for inclusion in the model 148 
were: measured creatinine clearance, estimated creatinine clearance (Cockroft-Gault 149 
formula), estimated glomerular filtration rate (Modification of Diet in Renal Disease 150 
(MDRD) formula), body weight, age, SOFA score and albumin, based on prior knowledge 151 
and biological plausibility  [4,24–27]. Body weight was included as a primary covariate on 152 
all model parameters, except for Km and Vmax, according to the allometric power model [28].  153 
(1) P Ti  = TVPT1*(WEIGHT/70)**power                         Eq. 1 154 
Where P Ti is the individual parameter value, TVPT1 is the parameter value for a typical adult 155 
with a body weight of 70kg, and power is an allometric exponent fixed to 0.75 for CL and Q 156 
and fixed to 1 for V and Vp. As an initial step, covariates measured creatinine, estimated 157 
creatinine clearance via Cockroft-Gault formula and estimated glomerular filtration rate using 158 
the MDRD formula were tested on the CL parameter as this is biologically plausible. 159 
 
However, only one of these was retained as correlated variables may lead to collinearity and 160 
inflation of the parameter’s standard error [29]. In a next step, forward selection and 161 
backward elimination using the PMstep function in Pmetrics was used to assess the 162 
relationship between covariates and model parameters. The log likelihood ratio test (LRT) 163 
and the Akaike information criterion (AIC) were considered during model building. More 164 
specifically, a difference of 3.84 in the log likelihood was considered significant at the 5% 165 
level when performing the likelihood ratio test for comparing nested models. Estimated 166 
parameters are reported as mean, percent coefficient of variation (%CV) and median with 167 
interquartile range (IQR). The %CV is reported as a measure of between-subject variability 168 
in the model parameters. 95% Confidence intervals were estimated via a non-parametric 169 
bootstrap (n=1000) and quantify the uncertainty on the parameter estimates. 170 
5. Pharmacokinetic model diagnostics 171 
The PopPK model was assessed by visual evaluation of the goodness of fit of the 172 
observed versus a posteriori predicted plots and the coefficient of determination of the linear 173 
regression of the observed-predicted values (r2 close to 1, intercept close to 0) from each run. 174 
The predictive performance was assessed on mean prediction error (bias) and the mean bias-175 
adjusted square prediction error (imprecision) of the population predictions.  176 
Internal model validation consisted of a visual predictive check (VPC) plot. The VPC 177 
(n=10.000) was performed by overlaying the 95% CI of the simulated profiles for 0.05, 0.5 178 
and 0.95 quantiles with the corresponding quantiles of the observed data. 179 
For external model validation, the final model population parameter distributions 180 
were used to predict concentrations for an independent validation dataset. We refer to 181 
Dhaese, et al [30] for a detailed description of this validation dataset. Prediction errors were 182 
evaluated based on the absolute bias (ME) and imprecision (MSE) as described in equation 2 183 
and 3: 184 
 
(2) Absolute bias[  ] (ME) = E[   –  ]                                                                            Eq.2 185 
(3) Absolute imprecision[  ] (MSE) = E[    –   2]                                                         Eq.3 186 
Where    is the predicted piperacillin concentration and   is the observed concentration. The 187 
root mean square prediction error (RMSE) was calculated by taking the square root of MSE. 188 
 189 
6. Comparative AUCu simulations for intermittent and continuous infusion dosing 190 
regimens  191 
Monte Carlo simulations (n=1000) were performed with the final PopPK model to 192 
compare the unbound (u) area under the curve (AUCu) as a measure of total (unbound) drug 193 
exposure between intermittent and continuous infusion dosing regimens. Using AUC as a 194 
basis to compare intermittent and continuous infusion of beta-lactam antibiotics was 195 
previously reported by Firsov and Mattie [31]. Free piperacillin concentrations were 196 
calculated assuming a 30% level of protein binding in accordance with previous findings  197 
[32]. Four different scenarios were evaluated; i.e. a daily dose of 12/1.5g TZP for a patient 198 
with a measured CLCR of 20mL/min, 16/2g TZP for a patient with a measured CLCR of 199 
70mL/min, 16/2g TZP for a patient with a measured CLCR of 130mL/min and 16/2g TZP for 200 
a patient with a measured CLCR of 200mL/min. The body weight for all patients was fixed at 201 
70kg. For each of these four scenarios, both intermittent and continuous infusion dosing 202 
regimens were simulated and compared. The AUCu was calculated using linear trapezoidal 203 
approximation. A 24-hour interval for AUCu calculation was chosen after six doses for 204 
intermittent infusion and one bolus and five maintenance doses for continuous infusion.  205 
 206 
7. Post hoc estimation of type I error rate  207 
A type I error rate analysis was performed to evaluate the probability to reject the null-208 
hypothesis (H0) in favor of the alternative hypothesis (H1) given that it is true, where H0 = 209 
 
piperacillin kinetics are best described by linear elimination and H1= piperacillin kinetics are 210 
best described by non-linear elimination. [27]  211 
In short, we simulated concentrations for 17 patients according to the design of this study 212 
(drug administration, blood sampling, etc.). For this, the PopPK model by Landersdorfer, et 213 
al [12] served as the H1, i.e. piperacillin PKs are non-linear and elimination is characterized 214 
by a parallel first-order and Michaelis-Menten process. The H0 was simulated by fixing the 215 
Vmax estimate in the model by Landersdorfer to zero, i.e. removing the non-linear component 216 
in piperacillin elimination. This process was repeated 5000 times, resulting in 10,000 217 
simulated datasets. All simulated datasets were fitted with a two-compartmental model with 218 
linear elimination and a two-compartmental model with parallel linear and Michaelis-Menten 219 
elimination. Both models were compared using the LRT according to equation 4.  220 
(4) LRT = 2*(LLc – LLr)                                                             Eq. 4 221 
where LLc is the log likelihood (LL) for the more complex model and LLr is the LL 222 
for the reduced model. The difference in the number of parameters between both models was 223 
4 when between-subject variability was included in the estimation of Km and Vmax and was 2 224 
otherwise. When considering the 5% level of significance, the critical values from the chi-225 
square distribution were 9.49 and 5.99, respectively.  226 
The type I error rate was calculated from the number of times the complex model was 227 
declared superior over the reduced model for the simulated datasets according to the H0.  228 
 229 
8. Statistical analysis 230 
All statistical analyses were performed using R and RStudio. Continuous data are 231 




1. Patients and samples 235 
In total, 17 patients were included, and 221 samples were collected (Table 1). All patients 236 
were enrolled between 5/2/2018 and 18/10/2018. Samples 5-7 were lost for patient 13 and 237 
sample 8 was lost for patient 15, therefore only 217 samples were analyzed and used for PK 238 
model building. The focus of infection was respiratory in 11 patients, abdominal in 5 patients 239 
and bacteremia in 1 patient.  240 
 241 
2. Pharmacokinetic model building and model diagnostics 242 
Table 2 summarizes the log-likelihood values, the coefficients of determination (r2 243 
values), the AIC’s and the predictive performance of linear, parallel linear and Michaelis-244 
Menten and Michaelis-Menten models (without covariates). Comparison of the coefficient of 245 
determination, the bias, imprecision and AIC indicated that the model with parallel linear and 246 
Michaelis-Menten kinetics was superior compared to both a model with linear elimination 247 
and a model with Michaelis-Menten elimination alone (Table 2).  248 
Including measured creatinine clearance (mCRCL) normalized to 100 mL/min as 249 
opposed to estimated creatinine clearance using the Cockroft-Gault or the estimated 250 
glomerular filtration rate using the MDRD formula provided the model with the lowest AIC 251 
value (Table 3). Forward selection and backward elimination further revealed a relationship 252 
between albumin and clearance. However, when including albumin as a covariate on CL, no 253 
model improvement in terms of 'AIC or LRT was noted, hence albumin was not retained as 254 
a covariate in the final model. 255 
The final model was described as: 256 
(5) CL = TVCL*(mCLCR/100) *(WEIGHT/70)**0.75             Eq. 5 257 
(6) V = TVV*(WEIGHT/70)                                                 Eq. 6 258 
(7) Vp = TVVp * (WEIGHT/70)                                                 Eq. 7 259 
 
(8) Q = TVQ* (WEIGHT/70)**0.75                                     Eq. 8 260 
where CL is piperacillin clearance, V is volume of distribution of the central compartment, 261 
Vp is volume of distribution of the peripheral compartment and Q is the intercompartmental 262 
clearance. TVCL refers to the population typical piperacillin clearance for a 70-kg patient 263 
with a mCLCR of 100 mL/min, TVV and TVVp refer to the population typical volume of 264 
distribution of the central, respectively the peripheral compartment for a 70-kg patient.  265 
 The mean, %CV, median (IQR) and %95 CI around the median for the population 266 
parameter estimates are listed in Table 4. The typical value for Km and Vmax was 37.09 mg/L 267 
and 353.57 mg/h respectively.  268 
Between-subject variability was not estimated on Km and Vmax as this resulted in an over-269 
parameterized model and an unacceptable inflation of the type I error rate (for further details 270 
see the section “Post hoc estimation of type I error rate”). Based on the diagnostic plots, the 271 
γ multiplicative error model was selected for modelling assay variance. In all model-building 272 
runs, each observation was weighted by 1/ (γ x SD2). We set γ equal to 1 initially and allowed 273 
Pmetrics to fit the value for the population. The final-cycle γ value was 1.26, indicating some 274 
additional process noise. The formula for the γ error model is error= γ*SD where SD is the 275 
standard deviation of each observation. SD is modeled by equation 9 and was based on 276 
earlier validation work by Carlier, et al [33]. 277 
(9) SD = 2 + 0.1x C                                                                                                       Eq. 9 278 
where C is the concentration of piperacillin. 279 
The a posteriori individual and population predicted versus observed plots and the 280 
VPC plots are shown in figure 2 and 3 respectively. The results of the Shapiro-Wilk test of 281 
normality for the NPDE indicated no violation of normality (p=.195). 282 
 
The final PopPK models showed a bias (ME) in predicting serum concentrations from the 283 
validation dataset of -20.8 (95% CI -26.2 ; -15.4) mg/L while imprecision (RMSE) was 49.2 284 
(95% CI 41.2 ; 56) mg/L. The Bland-Altman plot is shown in figure 4. 285 
 286 
3. Comparative AUCu simulations for intermittent and continuous infusion dosing 287 
regimens  288 
In all four scenarios, patients receiving continuous infusion had lower AUCu values when 289 
compared to simulated patients receiving the same dose via intermittent infusion (figure 5).  290 
 291 
4. Post hoc estimation of type I error rate  292 
If the between-subject variability was estimated for all model parameters, the type I error 293 
rate was 47.9%. If the between-subject variability was estimated for CL, Q, V and Vp and not 294 
estimated for Km and Vmax, the type I error rate was reduced to 6.6%. 295 
 296 
Discussion 297 
A PopPK model with parallel linear and Michaelis-Menten elimination of piperacillin 298 
best described this data, collected from 17 critically ill patients receiving both intermittent 299 
and continuous infusion piperacillin/tazobactam. These findings are in agreement with 300 
previous studies in healthy volunteers and non-critically ill patients [12,13,17] and in 301 
disagreement with other studies in healthy volunteers and critically ill patients [14,30,34].  302 
Renal excretion of piperacillin is the major pathway of elimination. Approximately 303 
74-89% of the administered dose of piperacillin is eliminated from the body by renal 304 
excretion [2,35]. More specifically, Tjandramaga, et al. [35] reported that 56-73% of the 305 
renally cleared piperacillin is eliminated through tubular secretion, which is a saturable 306 
process.  307 
 
Vmax is the maximum elimination rate for Michaelis-Menten elimination and the drug 308 
concentration at which the elimination rate is half of the maximum elimination rate is called 309 
the Michaelis-Menten constant or Km. Whether or not non-linear elimination of a drug is 310 
clinically relevant depends on the value of Vmax and Km. Non-linear elimination is a clinically 311 
relevant process if saturation occurs at therapeutic concentrations (i.e. Km within the 312 
therapeutic window) and if Vmax is high relative to CL, indicating a substantial contribution 313 
of the non-linear elimination process to the total body clearance. It is postulated that the non-314 
linear elimination pathway should contribute to at least 20% of the total body clearance for it 315 
to be clinically relevant [36]. If Km is very high, then saturation occurs but not at relevant 316 
plasma concentrations and it will therefore have no impact on the optimal dosing regimen 317 
[12]. Other researchers have reported Km estimates of 36.1 mg/L [12], 47.9 mg/L [13] and 318 
90.13 mg/L [17], all well in the range of therapeutic piperacillin plasma concentrations and in 319 
line with our estimate of 37.09 mg/L.  320 
The implications of these findings remain to be determined. Several institutions 321 
recently moved towards prolonged infusion of beta-lactam antibiotics yet conclusive 322 
evidence in favor of prolonged infusion is lacking and new clinical trials are in the pipeline 323 
[10,11,20,37]. Saturation of piperacillin elimination at therapeutic plasma concentrations is of 324 
particular relevance when randomized clinical trials compare intermittent versus continuous 325 
infusion piperacillin. Indeed, if saturation of piperacillin elimination occurs at therapeutic 326 
concentrations, clinical trials comparing the same daily dose of intermittent and continuous 327 
infusion piperacillin may unwillingly introduce a bias towards intermittent infusion as 328 
patients receiving the same daily dose of piperacillin via intermittent infusion may have a 329 
higher total antibiotic exposure when compared to patients receiving the same dose of 330 
piperacillin via continuous infusion as is demonstrated in the AUCu 24 calculations using the 331 
final PopPK model (figure 5). While AUCu/MIC may not be the PD index of choice for beta-332 
 
lactam antibiotics, the phenomenon of non-linear kinetics may impact antibiotic 333 
concentrations and indirectly also other PD indices such as T>MIC. This study focused on 334 
piperacillin but tubular secretion of other beta-lactam antibiotics such as amoxicillin, 335 
oxacillin, flucoxacillin, cefazolin and cefuroxime has been reported as well [38,39].   336 
When performing hypothesis testing and PK model selection, control of the type I 337 
error rate is pivotal to avoid false positive conclusions. Inflation of the type I error rate is 338 
expected when dealing with (very) small datasets [40,41]. In this study, including the 339 
between-subject variability on Km and Vmax resulted in an over-parameterized model and an 340 
unacceptable type I error rate (for further details see the section “Post hoc estimation of the 341 
type I error rate”). Therefore, the between-subject variability for Km and Vmax was not 342 
estimated. As few piperacillin population PK studies incorporate type I error calculations, it 343 
is difficult to determine how our findings with regard to the non-linear kinetics of piperacillin 344 
relate to the findings of other studies.  345 
This study has several limitations. While our primary goal was to detect non-linear 346 
elimination of piperacillin with a low probability of falsely rejecting H0, the between-subject 347 
variability was not estimated on Km and Vmax as this led to an unacceptable type I error. 348 
Determining urinary concentrations of renally eliminated drugs is helpful when non-linear 349 
kinetics are expected, however, in this study, piperacillin concentrations were not measured 350 
in the urine and no distinction could be made between the renal and non-renal clearance of 351 
piperacillin. The validation results indicate that the final model has a bias towards 352 
underpredicting antibiotic concentrations. While no bias is to be preferred, in case of 353 
underprediction, physicians may be inclined to increase the dose or dosing frequency. Given 354 
the low toxicity of beta-lactam antibiotics and the important risk of underdosing in ICU 355 
patients, models that underpredict concentrations of beta-lactam antibiotics are usually 356 
preferred over models that have bias towards overprediction [42]. Additionally, the sequence 357 
 
of the infusion modes never changed and all patients received continuous infusion first, 358 
followed by intermittent infusion. Hence, a trend in piperacillin clearance over time could not 359 
be excluded. 360 
In conclusion, piperacillin elimination was best described by a PopPK model 361 
incorporating parallel linear and Michaelis-Menten elimination. Nevertheless, in literature 362 
conflicting evidence is found on the importance of non-linear elimination for piperacillin PK. 363 
Non-informative study designs, and statistical inference based on over-parameterized models 364 
likely contribute to these conflicting findings. Future studies, appropriately powered and with 365 
a low type I error rate, should be conducted to provide conclusive evidence on the potential 366 
influence of non-linear elimination for piperacillin PK in critically ill patients.  367 
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Captions and legends of tables and figures 526 
Tables 527 
Table 1: Patient characteristics, laboratory data and infection characteristics 528 
 529 
Table 2: Predictive performance of linear and non-linear piperacillin population PK models 530 
Predictive performance of linear, parallel linear and Michaelis-Menten and Michaelis-Menten 531 
model. R2 is the coefficient of determination for the best-fit linear regression for the 532 
predicted-observed plot. LL is the log likelihood estimate. AIC is the Akaike information 533 
criterion. L = linear, MM= Michaelis-Menten. 534 
 535 
Table 3: Predictive performance of piperacillin population PK models incorporating renal 536 
clearance as a covariate 537 
Predictive performance of linear, parallel linear and Michaelis-Menten and Michaelis-Menten 538 
model. R2 is the coefficient of determination for the best-fit linear regression for the 539 
predicted-observed plot. LL is the log likelihood estimate. AIC is the Akaike information 540 
criterion. mCLCR = measured creatinine clearance, GaG = estimated creatinine clearance 541 
using the Cockroft-Gault formula, MDRD = estimated glomerular filtration rate using the 542 
MDRD formula. 543 
 544 
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Figures 551 
Figure 1: Administration of piperacillin and timing of sampling 552 
 553 
Figure 2: The population predicted versus observed concentrations (left) and the individual 554 
predicted versus observed concentrations (right) diagnostic plots for the final PK model. The 555 
dashed line is the line of unity and the solid line is the line of the best linear fit. 556 
 557 
Figure 3: Visual predictive check plot of piperacillin plasma concentrations (log10 scale) vs. 558 
time for the final PopPK model. Black dots represent observed data, solid lines represent 559 
quantiles of the observed data and dashed lines represent quantiles of the simulated data. 560 
 561 
Figure 4: Bland-Altman plot for comparison of predicted versus observed piperacillin 562 
concentrations from a validation dataset. The blue line represents the mean difference in 563 
concentrations. Red lines are mean-1.96*SD (lower line) and mean+1.96*SD (upper line).  564 
 565 
Figure 5: Simulations of mean (sd) AUCu values and time-concentration curves for a total 566 
daily dose of 12/1g PIP (upper graph) or 16g PIP via intermittent (left) or continuous (right) 567 
infusion for a patient with a body weight of 70kg and a measured CLCR of respectively 20, 568 
70, 130 and 200mL/min. AUCu values were calculated for a 24-hour interval after the sixth 569 
dose. 570 
